Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07773675
Starting soon Not applicable

The Effect of an Integrated Mobile Health Platform on Early Detection of Clinical Outcomes of Critical Ill Patients

NCT07773675 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sohag University
Phase
Not applicable
Started
2026-07-28
Last updated
2026-08-19

Condition(s) studied

Mobile Health PlatformClinical Outcomes

Investigational drug(s) / intervention(s)

Integrated Mobile Health Platform

Integrated Mobile Health Platform: A digital health platform integrated with ICU monitoring systems to automatically collect, record, and analyze patient vital signs and lab trends, generating real-time early warning alerts for healthcare providers.

Study summary

This study will aim to examine the Effect of integrated Mobile Health Platform on early detection of clinical outcomes of Critical ill patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Adult patients aged 18-65 years. 2. Anticipated ICU stay of more than 24 hours. 3. Clinical requirement and ability to continuously monitor vital signs and urine output. 4. Obtained written informed consent from the patient or their legal guardians. Exclusion Criteria: 1. Patients placed in strict isolation due to highly infectious diseases. 2. Death within 24 hours of ICU admission. 3. Patients transferred from another external Intensive Care Unit. 4. Re-admission to the ICU during the active study period. 5. Pre-existing chronic altered consciousness or irreversible neurological deficit. 6. Patients who underwent pre-hospital cardiopulmonary resuscitation (CPR).

Primary outcome measure(s)

  • ICU Mortality Rate — From ICU admission up to 30 days.
    The percentage of critically ill patients who die in the General Intensive Care Unit during their hospital stay. This will evaluate the impact of the mHealth platform on reducing patient mortality.

Trial sites (1)

FacilityCityRegionStatus
Sohag University Hospital, General Intensive Care Unit Sohag Sohag Governorate

More Sohag University trials in Egypt

Short-term Outcomes of High Tibial Osteotomy Using a Plate Versus a Plate With an Interbody Fusion Cage in Adolescent Tibia Vara : a Comparative Study Active, not recruiting
The Accuracy Of 3D Color Ultrasonography for Detecting the Degree of Placenta Accreta Spectrum Invasion Enrolling by invitation
Assessment of Risk Factors for Incisional Hernia Following Major Abdominal Surgery Recruiting
Serum Albumin in Acute Coronary Syndrome Starting soon
A Study of Endocrine, Metabolic, and Genetic Risk Factors of Pediatric Persistent Hypoglycemia at Sohag University Hospital Starting soon

Other trials for the same condition

Clinical and Radiographic Outcomes of Lesion Sterilization and Tissue Repair Using Zinc Oxide/ 6-gingerol Mix Versus Triple Antibiotic Paste in Non-vital Primary Molars Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07773675 on ClinicalTrials.gov ↗ ← All trials in Egypt